Royalty Pharma (RPRX) Gains from Investment Securities (2019 - 2026)

Royalty Pharma has disclosed Gains from Investment Securities across 8 years of filings, most recently posting $3.7 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $3.7 million, down 72.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (down 70.79% YoY), and the FY2025 annual result was $8.9 million, up 538.74% from the prior year.
• Gains from Investment Securities came in at $3.7 million for Q1 2026 at Royalty Pharma, up from $900000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $29.2 million in Q4 2022 to a low of -$16.3 million in Q2 2023.
• The 5-year median for Gains from Investment Securities is $3.9 million (2024), against an average of $6.3 million.
• Across the five-year window, Gains from Investment Securities tumbled 279.18% in 2022 and surged 433.34% in 2023, its largest moves.
• Royalty Pharma's Gains from Investment Securities stood at $29.2 million in 2022, then sank by 35.64% to $18.8 million in 2023, then tumbled by 97.34% to $500000.0 in 2024, then jumped by 80.0% to $900000.0 in 2025, then jumped by 313.56% to $3.7 million in 2026.
• The last three Gains from Investment Securities figures came in at $3.7 million (Q1 2026), $900000.0 (Q3 2025), and $600000.0 (Q2 2025), per Business Quant data.